Myasthenia Gravis, Ocular Myasthenia Gravis
Conditions
Keywords
myasthenia gravis, ocular myasthenia, apraclonidine
Brief summary
This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of ptosis secondary to myasthenia gravis.
Detailed description
The rationale behind using Apraclonidine is that it acts on Muller's muscle which is a sympathetic-innervated muscle. As such, this muscle is expected to be spared from the effects of the autoantibodies that attack the postsynaptic portion of the neuromuscular junction in myasthenia gravis.
Interventions
DRUGApraclonidine Hcl 0.5% Oph Soln
Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye
Sponsors
American University of Beirut Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients aged 18 or older with a diagnosis of ocular or generalized myasthenia gravis with ocular involvement.
Exclusion criteria
* Patients receiving mono-amino-oxidase inhibitors. * Patients with history of hypertension, cardiac, or cerebrovascular disease. * Women with confirmed pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in palpebral fissure height (PF) | Before administration, at 1, 5, 30, and 60 minutes after administration | Change in PF measurements |
| Change in marginal reflex distance-1 (MRD1) | Before administration, at 1, 5, 30, and 60 minutes after administration | Change in MRD1 measurements |
| Change in marginal reflex distance-2 (MRD2) | Before administration, at 1, 5, 30, and 60 minutes after administration | Change in MRD2 measurements |
| Change in levator function (LF) | Before administration, at 1, 5, 30, and 60 minutes after administration | Change in LF measurements |
Countries
Lebanon
Outcome results
None listed